OBJECTIVES The purpose of this study was to investigate the predictive values of baseline and changes in cystatin C (CysC) and its derived equations for short-term adverse outcomes and the effect of nesiritide therapy on CysC in acute decompensated heart failure (ADHF).
R enal insufficiency and worsening renal function (WRF) are prevalent in acute decompensated heart failure (ADHF), and they often coincide with diuretic unresponsiveness and inability to relieve congestion (1, 2) . This situation translates into worse outcomes associated with renal insufficiency and WRF. Hence, preservation of renal function is an important therapeutic goal in the treatment of acute heart failure. Although tubular functions are likely important as well, renal function has traditionally been quantified by its glomerular filtration rate (GFR). As the most frequently used marker of GFR, serum creatinine and its derived equations have thus become the mainstays of renal assessment in guiding management and risk stratification. However, because of variable production, dietary influence, dependence on muscle mass, and tubular secretion, the reciprocal relationship of serum creatinine with GFR has well-known limitations.
Cystatin C (CysC) is a small 13-kDa cysteine protease inhibitor that is ubiquitously produced at a fairly constant rate in all nucleated cells. It is freely filtered and neither secreted nor reabsorbed into the bloodstream. The general consensus has been that CysC is a more sensitive marker of early renal insufficiency (3, 4) . Several studies have suggested the prognostic role of baseline CysC levels in long-term adverse outcomes in the setting of ADHF (5, 6) , as well as in chronic stable heart failure (7) (8) (9) (10) . Meanwhile, newer estimates of GFR have also used CysC to achieve better prognostication in various stable clinical settings (8, (11) (12) (13) . As a result, there has been a strong emphasis on using CysC and CysC-derived equations in clinical practice, including the ADHF setting, in which renal dysfunction is common. However, prospective evaluations of clinical utility of serial CysC measurements or CysC-derived GFR estimates and their responses to therapeutic interventions have been less well established.
The ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure; NCT00475852) biomarker substudy creates a unique opportunity to investigate these questions (14) . Herein, we test the hypothesis that elevated CysC (and its derived GFR estimate) is associated with poor short-and intermediate-term prognosis. In particular, we aim to describe the prevalence and time course of CysC elevations in acute heart failure, the relationship of prevalent and incident CysC elevation to dyspnea response, 30-day clinical outcomes, and nesiritide response.
METHODS
STUDY POPULATION. The design and primary results of the main ASCEND-HF study have been described elsewhere (14, 15) . Briefly, ASCEND-HF was a multicenter randomized, double-blind, placebo- Dr. Metra is a consultant to and on the advisory board of Corthera, Daiichi, Novartis, and Servier. Dr. Anker has received honoraria from, is a consultant to, and is on the advisory board of Alere Inc., Europe, ThermoFisher Scientific, and Vifor Pharma. Dr. we adjusted the covariates identified from the overall ASCEND-HF study population (Online Table 1 ). Death Table 2 ). There were also no statistically significant differences between the 180-day death endpoint using baseline CysC and changes in creatinine (logtransformed, c-statistics 0.72 vs. 0.73, p ¼ 0.63). We further evaluated the incremental prognostic value of CysC when considering baseline estimates of renal function and observed that the prognostic value of CysC was negated in a similar fashion whether it was BUN or estimates of GFR using CKD-EPI equations that used creatinine, CysC, and both ( elevated CysC demonstrated the highest mortality risk at the 180-day visit. In contrast, differences between groups regarding hospital stay for heart failure were not as consistent (Online Table 3 (8, 17) .
Recent derivations of CysC-based equations have
further provided evidence to support the notion that these improved estimates of GFR can provide more precise and accurate prediction of adverse events in populations with chronic heart failure (13, 17, 19) .
Although higher baseline CysC portends poorer shortterm and long-term prognosis and identifies a tangw@ccf.org.
